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Regulatory T cells (Treg) mediate tolerance towards self-antigens by suppression of innate and adaptive immunity. In cancer
patients, tumor-infiltrating FoxP31 Treg suppress local anti-tumor immune responses and are often associated with poor
prognosis. Markers that are selectively expressed on tumor-infiltrating Treg may serve as targets for immunotherapy of
cancer. Here we show that CD103, an integrin mediating lymphocyte retention in epithelial tissues, is expressed at high
levels on tumor-infiltrating FoxP31 Treg in several types of murine cancer. In the CT26 model of colon cancer up to 90% of
the intratumoral FoxP31 cells expressed CD103 compared to less than 20% in lymphoid organs. CD1031 Treg suppressed T
effector cell activation more strongly than CD103neg Treg. Expression of CD103 on Treg closely correlated with intratumoral
levels of transforming growth factor b (TGF-b) and could be induced in a TGF-b-dependent manner by tumor cell lines. In vivo,
gene silencing of TGF-b reduced the frequency of CD1031 Treg, demonstrating that CD103 expression on tumor-infiltrating
Treg is driven by intratumoral TGF-b. Functional blockade of CD103 using a monoclonal antibody did however not reduce the
number of intratumoral Treg, indicating that CD103 is not involved in homing or retention of FoxP31 cells in the tumor tissue.
In conclusion, expression of CD103 is a hallmark of Treg that infiltrate TGF-b-secreting tumors. CD103 thus represents an
interesting target for selective depletion of tumor-infiltrating Treg, a strategy that may help to improve anti-cancer therapy.
Regulatory T cells (Treg) are crucial in the prevention of
autoimmunity by inhibiting effector T cell responses against
self-antigens.1 Treg however also inhibit immune responses
against malignant tumors and thus facilitate cancer develop-
ment.2 Indeed, a prominent role of Treg in tumor-associated
immunosuppression has been conﬁrmed by several recent
studies. During tumor progression Treg accumulate in the
blood and lymphoid organs of the tumor-bearing host and in
several types of cancer Treg abundantly inﬁltrate the tumor
tissue itself.2,3 Inhibition of anti-cancer immunity is mediated
predominantly by tumor-inﬁltrating Treg that suppress effec-
tor T cell responses locally at the tumor site.4 The number of
tumor-inﬁltrating FoxP3þ Treg is associated with poor prog-
nosis and has been identiﬁed as a signiﬁcant predictor of
patient death in several types of human cancer.5–7
Given the detrimental role of Treg in tumor progression,
efforts were made to identify target molecules to selectively
deplete these cells. The transcription factor FoxP3, the most
distinctive marker characterized so far for Treg in both
humans and mice, is not accessible to depleting antibodies
due to its intracellular expression.3 Natural thymus-derived
Treg constitutively express the interleukin-2 receptor a-chain
(CD25) and treatment of mice with monoclonal antibodies
against CD25 leads to a temporary reduction of
CD4þFoxP3þ cells.8 This enhances anti-tumor immunity
and can lead to T cell dependent rejection of pre-existing
tumors.9 However, with tumor progression the efﬁcacy of
anti-CD25 treatment is gradually reduced, a fact that may
result from simultaneous depletion of activated CD25-
expressing effector T cells.10 Another antibody-mediated
strategy to inhibit Treg function is the activation or blockade
of target molecules on these cells without depletion. Activa-
tion of the glucocorticoid-induced tumor-necrosis factor re-
ceptor related protein (GITR) by an agonistic antibody inhib-
its Treg function and shows in vivo anti-tumor activity.11,12
A blocking antibody to the cytotoxic T-lymphocyte-associ-
ated antigen 4 (CTLA4) expressed by both regulatory and
effector T cells inhibits Treg-induced suppression and is cur-
rently evaluated in clinical trials.3,13 Anti-CTLA4 treatment
however affects the entire pool of Treg and an important
limitation of this approach is the development of systemic
autoimmunity.14 A marker predominantly expressed by
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tumor-inﬁltrating Treg would represent a more selective tar-
get to enhance anti-cancer immunity.
The plasma membrane-associated molecule CD103, also
called aEb7, belongs to the family of integrins and is poorly
expressed by immune cells in the spleen or the peripheral
lymph nodes.15 CD103 can be detected mainly on T cell pop-
ulations within the mucosal epithelium of the gut and on in-
testinal lamina propria leukocytes.16 It is thought that CD103
contributes to the retention of lymphocytes in epithelial tis-
sues through interaction with its receptor E-cadherin
expressed by epithelial cells.17 Mice deﬁcient for CD103 have
slightly reduced numbers of intestinal intraepithelial lympho-
cytes, but apart from that are healthy, indicating that CD103
is probably dispensable.18 Among Treg in lymphoid tissues, a
subset of about 20% expresses CD103 and these cells display
an effector memory phenotype with low expression levels of
CD45RB and high levels of CD44.19 Some reports further
indicate that CD103þ Treg more strongly inhibit CD4 T cell
proliferation than conventional Treg.19,20 Thus, CD103 is a
surface-expressed molecule that marks both intestinal lym-
phocytes and a particularly suppressive subtype of Treg.
In this study, we analyzed tumor-inﬁltrating Treg for
expression of CD103 in four different murine models of can-
cer. In all tumor models, we found that the majority of intra-
tumoral Treg express CD103 with up to 90% of FoxP3þ
Treg staining positive for CD103. High proportions of
CD103þ cells were further speciﬁc for tumor-inﬁltrating
Treg. CD103 expression on Treg correlated with TGF-b
secretion of tumor cells and could be down-regulated by
RNAi-mediated gene silencing of TGF-b. Therapeutic target-
ing of CD103 may represent a promising approach to
enhance anti-cancer immunity.
Material and Methods
Mice and cell lines
Female BALB/c and C57BL/6 mice were purchased from Har-
lan-Winkelmann (Borchen, Germany). Mice were 5 to 10
weeks of age at the onset of experiments. Animal studies were
approved by the local regulatory agency (Regierung von Ober-
bayern, Munich, Germany). The murine cell lines Colon-26
(CT26; Cell Lines Service, Heidelberg, Germany), B16 mela-
noma F1 (LGC Promochem, Teddington, UK), EL-4 lym-
phoma (Institute of Immunology, University of Munich) and
Panc02 (kindly provided by Prof. C. Bruns, Department of Sur-
gery, University of Munich) were maintained in DMEM me-
dium supplemented with 10% FCS, 1% L-glutamine, 1 U/ml
penicillin and 0.1 mg/ml streptomycin (all PAA Laboratories,
Coelbe, Germany). For tumor induction 0.25  106 (CT26), 1
 106 (B16 and Panc02), or 5  106 (EL4) tumor cells were
injected subcutaneously into the ﬂank. The tumor-draining
lymph nodes were identiﬁed by connecting vessels, the proxim-
ity to the tumor and the larger size compared to non-draining
lymph nodes. Tumor size was expressed as the product of the
perpendicular diameters of individual tumors (mm2). Tumor
growth was calculated as ﬁnal tumor size divided by the num-
ber of days since injection (mm2/d) to normalize data from in-
dependent experiments.
Immunohistology
Tumor tissues were frozen in liquid nitrogen and 5 lm cryo-
sections from the center of the tumors were prepared. The
following primary antibodies were used: anti-mouse CD103
(Biolegend, San Diego, CA), anti-mouse FoxP3 (Ebioscience,
San Diego, CA) and anti-mouse E-Cadherin (Cell Signaling
Technology, Beverly, MA). Cy5 F(ab)2 goat anti-Armenian
hamster IgG, biotin F(ab)2 donkey anti-rat IgG, biotin IgG
donkey anti-rabbit IgG and rhodamin red X streptavidin
were used as detection reagents. Nucleic counterstaining was
performed using DAPI (Sigma Aldrich, Steinheim, Germany).
Counting was performed blinded by two independent investi-
gators. Images were obtained by ﬂuorescence microscopy
(Axiovert 2000 Carl Zeiss, Jena, Germany; 40-fold magniﬁca-
tion) using Carl Zeiss Axiovision software and processed
with Adobe Photoshop for adjustment of contrast and size.
Flow cytometry
For ﬂow cytometry analysis single cell suspensions of spleen,
lymph nodes or Peyer’s patches were prepared. Bone marrow
cells were harvested from murine femur and tibia and eryth-
rocytes were lysed with ammonium chloride buffer (BD Bio-
sciences). To isolate lymphocytes from tumor, lung, liver or
heart, the tissues were mechanically disrupted, incubated with
1 mg/ml collagenase and 0.05 mg/ml DNAse (both Sigma
Aldrich) and subsequently passed through a cell strainer. Sin-
gle cell suspensions were resuspended in 44% Percoll (Bio-
chrome, Berlin, Germany) and layered over 67% Percoll prior
to centrifugation at 800 g for 30 min. Lymphocytes from the
interphase were stained for ﬂow cytometry. The following
antibodies were used: Paciﬁc Blue or PerCP anti-mouse CD3,
PE anti-mouse B220, PE-Cy7 or PerCP anti-mouse CD4,
APC-Cy7 anti-mouse CD8 (all Biolegend), FITC anti-mouse
CD103 (BD Biosciences, Heidelberg, Germany) and Paciﬁc
Blue or APC anti-mouse FoxP3 (Ebioscience). Intracellular
detection of FoxP3 was performed using premixed regulatory
T cell staining reagents (Ebioscience). Events were measured
on a FACS Calibur or FACS Canto II ﬂow cytometer (BD
Biosciences) and analyzed with FlowJo software (TreeStar,
Ashland, OR).
FACS sorting and proliferation assays
Untouched CD4þ T cells were sorted from single cell sus-
pensions of lymph nodes by magnetic cell sorting (Miltenyi
Biotec, Bergisch Gladbach, Germany). Cells were stained with
labeled antibodies against CD103 (Fitc, BD Biosciences), CD4
(PerCP) and CD25 (APC, both from Biolegend). CD4þ
CD25þ CD103þ, CD4þCD25þCD103neg and CD4þ
CD25neg cells were obtained by FACS sorting using a FACS
Aria cell sorter (BD Biosciences) with a purity of more than
99%. Treg subsets (3  104 cells) and T effector cells (7.5 
104 cells) were cultured in triplicate with anti-CD3-CD28
beads (Invitrogen, Carlsbad, CA) at a bead-to-cell ratio of 1:5

ht
tp
://
do
c.
re
ro
.c
h
for 72 hr and in the presence of BrdU (Roche Diagnostics,
Mannheim, Germany). To detect proliferation of T effector
cells, co-cultures were then stained with Paciﬁc Blue-labeled
FoxP3 antibody, ﬁxed with 1% PFA in PBS, incubated with
DNAse I (0.05 mg/ml in PBS; Sigma-Aldrich, Steinheim,
Germany) and further stained with anti-BrdU-FITC antibody
(Invitrogen). T effector cell proliferation and activation was
determined by BrdU and CD69 expression of CD4þFoxP3neg
cells. IL-2 levels in the co-culture were measured by ELISA
(BD Biosciences).
TGF-b in vitro assays
To assess CD103 induction on Treg, 1.2  105 splenocytes
were cultured in triplicate with supernatants of CT26 or EL-4
tumor cells in the presence of anti-CD3-CD28 coated
microbeads (Invitrogen, bead to cell ratio 1:10). Recombinant
TGF-b1 or anti-TGF-b1 antibody (both R&D Systems, Min-
neapolis, MN) were added in a concentration of 5 ng/ml and
12.5 lg/ml, respectively. Cells were cultured for three days
before analysis by ﬂow cytometry.
TGF-b ELISA of supernatants and tissue lysates
To measure TGF-b secretion by different tumor cell lines, 5
 106 tumor cells were plated in 3 ml of medium, cultured
for two days and supernatants were analyzed by ELISA
(R&D Systems). For analysis of tissues, tumor or lymph node
homogenates were resuspended in lysis buffer (BioRad
Laboratories, Hercules, CA) and centrifuged. Total protein
concentration was measured by Bradford assay (BioRad Lab-
oratories). All samples were diluted to equal protein concen-
trations and TGF-b1 levels were measured by ELISA. The
ﬁnal cytokine concentration was calculated as ng cytokine/g
protein in the respective lysate.
TGF-b gene silencing and in vivo CD103 blocking
For in vivo gene silencing of TGF-b, siRNAs were designed
according to published guidelines.21 30-Overhangs were car-
ried out as two deoxythymidine residues (dTdT). RNAs were
all from Euroﬁns MWG Operon (Penzberg, Germany).
Sequences were: Control RNA: 50-GAUGAACUUCAGGGU
CAGCG-30 (sense), 50-CGCUGACCCUGAAGUUCAUC-30
(antisense); TGF-b1 siRNA: 50-GAACUCUACCAGAAAU
AUAUU-30 (sense), 50-AAUAUAUUUCUGGUAGAGUUC-
30 (antisense). Nonsilencing siRNA (control RNA) was
designed to contain random sequences that do not match
within the murine or human genome. For in vivo delivery 50
lg of siRNA was complexed with in Vivo JetPEI reagent
(Peqlab, Erlangen, Germany) according to the manufacturer’s
instructions and injected into the tail vein. For in vivo block-
ing of CD103, 150 lg of rat IgG2aj anti-mouse CD103 anti-
body (clone M290, Bioxcell, West Lebanon, NH) was injected
intraperitoneally.
Statistics
All data are presented as mean þ/ SEM and were analyzed
as appropriate by unpaired Student’s t-test or by ANOVA
test using the Student Newman Keuls test. Statistical analysis
was performed using SPSS software.
Results
A high proportion of tumor-inﬁltrating FoxP31 regulatory
T cells expresses CD103
To investigate CD103 expression levels on tumor-inﬁltrating
Treg, subcutaneously induced murine CT26 colon and B16
melanoma tumors were examined by immunoﬂuorescence
staining. Tissue sections were double-stained with antibodies
directed against FoxP3 and CD103 and the proportion of
CD103þ Treg was evaluated by counting non-overlapping
visual ﬁelds from tumors of eleven different mice (Fig. 1a).
Strikingly, in CT26 tumors more than 90% of the tumor-
inﬁltrating FoxP3þ cells expressed the integrin CD103 (Fig.
1b). In contrast, in the spleen only 20% of FoxP3þ cells were
positive for CD103, consistent with previous reports.22 In
subcutaneous B16 melanoma tumors, more than 50% of
intratumoral Treg expressed CD103 (Fig. 1b). We further
used ﬂow cytometry to analyze CD103 levels on tumor-inﬁl-
trating FoxP3þ cells and could conﬁrm the high proportion
of CD103þ Treg in both CT26 and B16 tumors (Fig. 1c).
Analysis of an additional tumor model, the subcutaneous EL-
4 lymphoma, revealed a lower percentage of CD103þ cells
within tumor-inﬁltrating Treg (31%) compared to the CT26
and B16 tumors. In all analyzed models, however, CD103
expression of intratumoral Treg was signiﬁcantly higher com-
pared to FoxP3þ cells in the spleen of the same mice (Fig.
1c). Further, expression levels of CD103 by tumor-inﬁltrating
Treg clearly correlated with tumor growth (Fig. 1d). To con-
ﬁrm previous reports indicating that CD103þ cells represent
a particularly suppressive subset of Treg19,20 we isolated
CD103þ and CD103neg Treg from CT26 tumor-bearing
mice. Indeed, CD103þ Treg more strongly suppressed prolif-
eration, activation and IL-2 release of T effector cells (Fig.
1e). In conclusion, tumor-inﬁltrating Treg are characterized
by high expression levels of CD103, a marker predicting
potent suppressive function of these cells.
High expression of CD103 is speciﬁc for tumor-inﬁltrating
regulatory T cells
To assess whether the high proportions of CD103þ cells are
speciﬁc for tumor-inﬁltrating Treg, we determined the per-
centage of CD103þ cells within FoxP3þ cells derived from
different organs of tumor-bearing mice. In the peripheral
lymph nodes, numbers of CD103þ cells among Treg were
generally low with a proportion of less than 25% (Fig. 2a).
Interestingly, in CT26 tumor-bearing mice a signiﬁcantly
higher number of CD103-expressing Treg was detected in the
tumor-draining lymph nodes. To assess CD103 expression in
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Figure 1. CD103 is highly expressed by tumor-inﬁltrating Treg. CT26, B16, and EL-4 tumors were induced by subcutaneous injection of the
respective tumor cell line. Tumors were isolated and analyzed by immunohistology or ﬂow cytometry when they reached a mean size of
100 mm2. (a) Tissue sections of CT26 tumors were stained for CD103 (green) and FoxP3 (red) and representative images of CD103þ and
CD103neg Treg are shown. (b) The proportion of CD103þ cells within FoxP3þ cells was determined in CT26 (n ¼ 6) and B16 tumors (n ¼
5) and in the spleen of a C57BL/6 mouse (n ¼ 1). Each data point represents the proportion of CD103þ cells within FoxP3þ cells in the
tumor or the spleen of one mouse. (c) Expression of CD103 was determined by ﬂow cytometry on CD4þFoxP3þ cells isolated from the
spleen and the tumor tissue of CT26 (n ¼ 6), B16 (n ¼ 5), or EL-4 (n ¼ 6) tumor-bearing mice. The mean percentage of CD103þ cells
among CD4þFoxP3þ cells for all mice is shown. (d) Tumor growth of CT26 tumors in mm2/day from three independent experiments was
correlated to CD103 expression of CD4þFoxP3þ tumor-inﬁltrating cells according to Pearson’s test. (e) CD4þCD25þCD103þ and
CD4þCD25þCD103neg Treg as well as CD4þCD25neg T effector cells were isolated by FACS sorting from the tumor-draining lymph nodes of
CT26 tumor-bearing mice. T effector cells were co-cultured with either Treg subset in the presence of anti-CD3-CD28 antibody. Proliferation
and activation of T effector cells was measured by incorporation of BrdU, expression of CD69 and secretion of IL-2 using ﬂow cytometry or
ELISA. Error bars indicate SEM. P values for (b and c) were calculated relative to the proportion of CD103þ cells in the spleen and for (e)
relative to suppression by CD103neg Treg (*p < 0.05; ***p < 0.001). [Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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other compartments, we isolated lymphocytes from lung,
heart, liver, Peyer’s patches, and bone marrow and deter-
mined CD103 expression by Treg. In all organs analyzed, the
proportion of CD103þ cells among Treg was comparable to
those in the peripheral lymph nodes (Fig. 2b). To further
determine the proportion of CD103þ cells among other lym-
phocyte subsets, we analyzed B220þ, CD4þFoxP3neg, and
CD8þ cells. Expression of CD103 was observed only on a
small proportion of all lymphocyte subtypes, both in the
spleen and the tumor tissue (Fig. 2c). Thus, high numbers of
CD103þ cells are speciﬁc for tumor-inﬁltrating Treg.
Expression of CD103 in tumor-inﬁltrating regulatory T cells
is driven by intratumoral transforming growth factor b
We next examined the mechanism responsible for enhanced
CD103 expression on tumor-inﬁltrating Treg. In gut-associ-
ated lymphoid tissue, CD103 expression by lymphocytes is
known to be induced by transforming growth factor b (TGF-
b)16 and thus, we hypothesized that cancer-associated TGF-b
may give rise to high CD103 levels on tumor-inﬁltrating
Treg. As signiﬁcant differences were seen in the proportion
of CD103þ cells among Treg within different tumor models
(Fig. 1c), we quantiﬁed tumor-associated TGF-b levels to es-
tablish a possible relation. Cell culture supernatants as well as
tissue lysates of CT26, B16, and EL-4 tumors were analyzed
by ELISA. Whereas high and intermediate levels of TGF-b
were detected in the supernatants of CT26 and B16 cells,
respectively, EL-4 tumor cells did not produce this growth
factor (Fig. 3a). In vivo, a similar pattern of TGF-b levels was
observed, with the lowest levels of this cytokine in EL-4
tumors (Fig. 3b). Both in vitro and in vivo levels of TGF-b
correlated with CD103 expression by tumor-inﬁltrating Treg,
with high levels of both parameters in CT26 and B16 tumors.
As CD103þ Treg were more frequent in tumor-draining
than in contralateral lymph nodes we also compared TGF-b
levels in these organs. Indeed, in the tumor-draining lymph
nodes we detected signiﬁcantly higher amounts of TGF-b
than in non-draining lymph nodes in all but one mouse, thus
conﬁrming the positive correlation with CD103 expression
(Fig. 3c).
Figure 2. High expression of CD103 is characteristic for tumor-inﬁltrating Treg. (a) Subcutaneous tumors were induced as described in
Figure 1 and lymph nodes were isolated when tumors reached a mean size of 100 mm2. Expression of CD103 on CD4þFoxP3þ cells
derived from both tumor-draining and contralateral lymph nodes was analyzed by ﬂow cytometry (CT26, n ¼ 6; B16, n ¼ 5 and EL-4, n ¼
6). p values were calculated relative to the proportion of CD103þ cells in the contralateral lymph node (**p < 0.01). (b) The bar diagram
shows the proportion of CD103þ cells among CD4þFoxP3þ cells isolated from the indicated organs of healthy BALB/c mice (n ¼ 6; LN,
lymph nodes; BM, bone marrow and PP, Peyer’s patches). (c) The proportion of CD103þ cells among B220þ, CD4þFoxP3neg and CD8þ
cells derived form the spleen and the tumor of CT26-bearing mice was analyzed by ﬂow cytometry. Error bars indicate SEM.
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To investigate whether tumor-associated TGF-b triggers
CD103expression by Treg, we cultured splenocytes in
supernatants from CT26 tumor cells and quantiﬁed the
proportion of CD103þ cells within CD4þFoxP3þ Treg.
Indeed, CT26 supernatants induced CD103 expression by
Treg and blocking of TGF-b efﬁciently prevented CD103
induction (Fig. 4a). In contrast to CT26, supernatants of
TGF-b-negative EL-4 tumor cells did not induce CD103 on
Treg. A clear up-regulation of CD103 on Treg was however
observed upon addition of recombinant TGF-b to EL-4
supernatants (Fig. 4b) or by recombinant TGF-b alone (not
shown). These data demonstrate that CD103 expression on
Treg is directly triggered by tumor cell-derived TGF-b.
Interestingly, this effect was speciﬁc for FoxP3þ Treg, as
no induction of CD103 was seen on CD4þFoxP3neg or
CD8þ T cells (Fig. 4c). The role of TGF-b in CD103
induction on Treg was further assessed in vivo by siRNA-
mediated knock-down. Treatment of tumor-bearing mice
with a TGF-b siRNA signiﬁcantly reduced intratumoral lev-
els of TGF-b, as determined by ELISA of tissue lysates
(Fig. 4d). We then analyzed CD103 expression by tumor-
inﬁltrating FoxP3þ cells using immunohistology. In mice
treated with a control RNA nearly 50% of intratumoral
Treg expressed CD103. Strikingly, a signiﬁcant decrease of
CD103 expression by Treg was observed upon treatment
with the TGF-b-speciﬁc siRNA (Figs. 4e and 4f). In conclu-
sion, expression of CD103 by tumor-associated Treg is
driven by TGF-b.
CD103 is not required for the retention of regulatory
T cells in the tumor
CD103 is an integrin that mediates retention of lymphocytes
in epithelial tissues.17 To assess whether expression of CD103
is necessary for the homing and retention of Treg in malig-
nant tumors, we treated tumor-bearing mice with a blocking
antibody against CD103. The monoclonal rat anti-mouse
CD103 antibody (clone M290) binds to the aE-subunit and
blocks the interaction of CD103 with its receptor E-cadherin,
but does not deplete CD103þ cells.23,24 Treatment with anti-
CD103 antibody was started one week after tumor induction
and inﬁltration by FoxP3þ cells was evaluated 10 days later.
We observed no differences in the number of tumor-inﬁltrat-
ing FoxP3þ cells between untreated and anti-CD103 treated
mice (Fig. 5a). Efﬁcient delivery of the antibody was con-
ﬁrmed by showing in vivo binding of M290 to CD103; this
was demonstrated by staining frozen tumor sections of
treated mice with a ﬂuorescence-labeled anti-rat antibody
(Fig. 5b). Anti-CD103 treatment further did not alter Treg or
CD8 T cell numbers in the tumor-draining lymph nodes
(Figs. 5c and 5d) or the spleen (data not shown) and had no
impact on tumor growth (Fig. 5e). In addition, we found that
the only known receptor for CD103, E-cadherin, is not
expressed within CT26 tumors (Fig. 5f). Thus, although the
majority of FoxP3þ cells expresses CD103, this integrin
appears not to be required for the retention of Treg in the
tumor tissue. Therapeutic targeting of CD103þ cells will
therefore require the use of an antibody with depleting rather
Figure 3. Tumor-derived TGF-b secretion correlates with CD103 expression by Treg. (a) Equal numbers of CT26, B16 and EL-4 tumor cells
were cultured in triplicate for two days and TGF-b levels in the supernatant were determined by ELISA. (b and c) Subcutaneous tumors were
induced as described in Figure 1 and isolated when they reached a mean size of 100 mm2. TGF-b levels were determined by ELISA in
tissue lysates of the respective tumors (CT26, n ¼ 6; B16, n ¼ 4 and EL-4, n ¼ 5) and of the tumor-draining and contralateral lymph nodes
derived from CT26-bearing mice. The concentration of TGF-b in the tumor-draining lymph nodes is shown relative to the contralateral lymph
nodes (set at 100%) for each mouse. Error bars indicate SEM. p values were calculated as indicated by the lines (*p < 0.05; **p < 0.01;
***p < 0.001).
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than blocking function. The development of such an antibody
could be a promising approach for cancer immunotherapy.
Discussion
Treg inhibit immune responses against malignant tumors
and represent an important obstacle for cancer immunother-
apy.3 In particular, Treg inﬁltrating the tumor tissue itself in-
hibit anti-cancer immunity and correlate with poor prognosis
in many types of human cancer.4,5,25 A comprehensive
knowledge of the phenotype of tumor-inﬁltrating Treg is cru-
cial to understand their mode of action and to develop thera-
peutic strategies that target these cells. In this study, we dem-
onstrate that the majority of tumor-inﬁltrating Treg expresses
CD103, a cell surface protein of the integrin family. In CT26
tumors more than 90% of Treg expressed CD103 and a high
proportion of CD103þ cells within intratumoral FoxP3þ
Treg was observed in three other models of murine cancer.
In contrast, analysis of CD103 expression by Treg in a broad
panel of peripheral organs including the spleen, lymph nodes,
lung, liver, heart, bone marrow, and Peyer’s patches revealed
Figure 4. Expression of CD103 on tumor-inﬁltrating Treg is mediated by TGF-b. (a–c) Freshly isolated splenocytes (1.2  105) were
stimulated with anti-CD3-CD28 coated microbeads and cultured with supernatants of CT26 or EL-4 tumor cells in the presence of either
TGF-b blocking antibody or recombinant TGF-b. CD103 expression on CD4þFoxP3þ, CD4þFoxP3neg (Teff) and CD8þ T cells was determined
by ﬂow cytometry after three days. (d–f) Subcutaneous Panc02 tumors of C57BL/6 mice were treated with a siRNA (50 lg i.v.) directed
against TGF-b1 (n ¼ 4) or with an irrelevant control RNA (n ¼ 3) 10 days after induction. siRNA treatment was repeated after 36 hr and 12
hr later tumors were removed for analysis by ELISA and immunohistology. TGF-b levels were determined by ELISA in tissue lysates of RNA-
treated tumors (d). Tumor sections were double-stained for CD103 (green) and FoxP3 (red) and two representative images are shown for
both control RNA and TGF-b siRNA-treated mice (e). The proportion of CD103þ cells within FoxP3þ cells was determined in both groups by
counting non-overlapping visual ﬁelds. Each data point represents the mean proportion of CD103þ cells within FoxP3þ Treg in the tumor
of one mouse and bars indicate the mean of one treatment group (f). Error bars indicate SEM. p values were calculated relative to control
RNA-treated mice (*p < 0.05). [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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only low expression levels with about 20% CD103þ cells
among FoxP3þ Treg. Thus, in cancer-bearing hosts high
expression of CD103 is a unique property of tumor-inﬁltrat-
ing Treg. Previous work has shown that positivity for CD103
deﬁnes a subset of Treg with speciﬁc migratory and anti-
inﬂammatory properties: CD103þ Treg express a set of che-
mokine receptors similar to activated T cells and thus prefer-
entially home to sites of inﬂammation.22 The speciﬁc pattern
of chemokine receptor expression could thus explain the
accumulation of these cells in malignant tumors. An impor-
tant property of CD103þ Treg is their highly suppressive
function: CD25þCD103þ Treg inhibit effector T cell prolif-
eration more potently than CD25þCD103neg cells19,20 and
tumor-derived CD103þ Treg suppress CD8 T cell responses
more strongly than CD103neg Treg.26 The prevalence of
CD103þ Treg that we observed in several types of tumors
may therefore enhance immunosuppression. We conclude
that CD103 represents an interesting molecule to
Figure 5. CD103 is not required for the retention of Treg in the tumor tissue. (a–e) Seven days after induction of subcutaneous CT26
tumors mice received intraperitoneal injections of 150 lg monoclonal rat anti-mouse CD103 antibody every second day (clone M290) or
remained untreated (n ¼ 6 for each group). Tumors were removed ten days after the ﬁrst treatment and analyzed by immunohistology. (a)
Representative images and quantiﬁcation of tumor-inﬁltrating FoxP3þ cells (n ¼ 3 for each group). (b) Frozen tissue sections of untreated
and anti-CD103-treated tumors were stained with biotin-conjugated anti-rat IgG antibody, followed by ﬂuorescence-conjugated streptavidin
(green) for the in vivo detection of the monoclonal rat-anti mouse CD103 antibody. (c and d) The proportion of CD4þFoxP3þ cells and
CD8þ cells within CD3þ cells in the tumor-draining lymph node was determined by ﬂow cytometry. (e) Tumor growth of both untreated and
anti-CD103 treated mice was determined. Error bars indicate SEM. p values were calculated relative to untreated mice (n.s., not
signiﬁcant). (f) Untreated tumor tissues of CT26 tumors (experiment described in Fig. 1) were analyzed by immunohistology for the
expression of E-cadherin (green) and kidney sections from healthy mice were used as positive control. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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therapeutically target a tumor-resident and highly immuno-
suppressive Treg subset.
Due to the central role of Treg in tumor-associated immu-
nosuppression, targeting these cells by speciﬁc antibodies is a
promising approach. Depleting antibodies against CD25 have
been extensively tested and show some efﬁcacy in mice, but
lack signiﬁcant beneﬁts in patients so far.27 A blocking
antibody against CTLA-4, a receptor expressed by T cells,
synergistically enhances anti-tumor immunity by inhibiting
Treg-induced suppression and promoting T effector cell acti-
vation28; this treatment can however lead to systemic autoim-
munity as CTLA-4 is ubiquitously expressed.14 For CD103,
we have shown predominant expression by Treg in the tu-
mor tissue and to some extent in the tumor-draining lymph
node. Thus, targeting this molecule could eliminate Treg at
the sites where they most potently suppress tumor-speciﬁc
immunity. Unfortunately, a depleting antibody against
CD103 has so far not been developed. In mice, only antibod-
ies of the rat IgG2b and to some extent of the IgG1 isotype
bear the potential to induce antibody-mediated cytotoxicity
leading to depletion of target cells.29,30 In this study we used
the monoclonal rat IgG2aj antibody M290, which blocks the
interaction of CD103 with its receptor E-cadherin.23,24 As
expected, M290 treatment did not deplete CD103þ cells.
However, we speculated that anti-CD103 treatment could
reduce Treg numbers via interfering with the retention of
Treg within the tumor. The principal function of CD103 is
to mediate adhesion of cells in epithelial tissues17 and for
Treg, it has been shown that CD103 is essential for the reten-
tion in inﬂamed skin during infection with the parasite
Leishmania major.31 As Treg numbers were not altered by
anti-CD103 treatment, our data show that CD103 is not
involved in the retention of Treg within malignant tumors.
This is further supported by the lack of E-cadherin expres-
sion in the tumor tissue, the so far only identiﬁed ligand for
CD103. Thus, blocking CD103 is not sufﬁcient to suppress
tumor inﬁltration by Treg, but generation of depleting anti-
bodies will be an interesting approach for immunotherapy of
cancer.
As CD103 does not mediate retention of Treg in the tu-
mor tissue, another mechanism must be responsible for the
accumulation of intratumoral FoxP3þ cells expressing this
integrin. Our data suggest that intratumoral TGF-b promotes
the expression of CD103 on tumor-inﬁltrating Treg. We
found that high levels of CD103 were expressed predomi-
nantly in those types of tumors with strong TGF-b secretion.
In addition, in vivo gene silencing of TGF-b reduced the
number of intratumoral CD103þ Treg. Our hypothesis is
supported by previous reports showing that TGF-b is a
potent inducer of CD103 in vitro.32,33 Further, in vivo TGF-
b mediates expression of CD103 by intraepithelial and lam-
ina propria-associated lymphocytes16 and induces the genera-
tion of CD103-expressing FoxP3þ Treg from naı¨ve T cells.34
The high number of tumor-inﬁltrating CD103þ Treg could
thus result from the conversion of previously nonregulatory
T cells. In conclusion, CD103 represents a good marker to
selectively target Treg in TGF-b-secreting tumors and the
development of novel depleting antibodies against CD103
may be a promising approach to improve anti-cancer
therapy.
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